Viridian Therapeutics (LTS:0K1R) Short Percentage of Float

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

LTS:0K1R Viridian Therapeutics Inc LTS:0K1R
51 GF Score
Price $23.38
GF Value $1,352.73
Valuation Possible Value Trap
! 5 Warning Signs
View Full Analysis

What is Viridian Therapeutics Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

LTS:0K1R vs BHVN, AGIO, SION: Short Percentage of Float Comparison

For the Biotechnology subindustry, Viridian Therapeutics's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Viridian Therapeutics Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Viridian Therapeutics's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Viridian Therapeutics's Short Percentage of Float falls into.


LTS:0K1R
51GF Score
Viridian Therapeutics Inc LTS:0K1R
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Viridian Therapeutics (LTS:0K1R) Overvalued in 2026?

Based on GuruFocus' analysis, Viridian Therapeutics stock appears to be undervalued. The current stock price of $23.38 is trading 98.3% below its estimated GF Value™ of $1,352.73. GuruFocus considers Viridian Therapeutics to be Possible Value Trap.

Key valuation signals for LTS:0K1R:

  • Short Percentage of Float:
  • GF Value™: $1,352.73 vs. price of $23.38 (98.3% below fair value)
  • GF Score™: 51/100 with 5 warning signs

No single metric tells the full story. See the LTS:0K1R stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Viridian Therapeutics Business Description

Other Exchanges VRDN:USA1S1:Germany
Address 221 Crescent Street, Suite 103A, Waltham, MA, USA, 02453
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.
51GF Score

Get the complete analysis for LTS:0K1R

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$23.38
Price
$1,352.73
GF Value